Vistagen Therapeutics (VTGN) Stock Overview
A clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
VTGN Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Vistagen Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.65 |
| 52 Week High | US$5.14 |
| 52 Week Low | US$0.43 |
| Beta | 0.30 |
| 1 Month Change | 7.40% |
| 3 Month Change | 15.72% |
| 1 Year Change | -73.15% |
| 3 Year Change | -83.62% |
| 5 Year Change | -99.17% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| VTGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.5% | 1.2% | 1.0% |
| 1Y | -73.2% | 34.9% | 28.7% |
Return vs Industry: VTGN underperformed the US Biotechs industry which returned 34.4% over the past year.
Return vs Market: VTGN underperformed the US Market which returned 27.1% over the past year.
Price Volatility
| VTGN volatility | |
|---|---|
| VTGN Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VTGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VTGN's weekly volatility has decreased from 16% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 59 | Shawn Singh | www.vistagen.com |
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women’s health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders.
Vistagen Therapeutics, Inc. Fundamentals Summary
| VTGN fundamental statistics | |
|---|---|
| Market cap | US$25.24m |
| Earnings (TTM) | -US$67.05m |
| Revenue (TTM) | US$789.00k |
Is VTGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VTGN income statement (TTM) | |
|---|---|
| Revenue | US$789.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$789.00k |
| Other Expenses | US$67.84m |
| Earnings | -US$67.05m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.69 |
| Gross Margin | 100.00% |
| Net Profit Margin | -8,497.59% |
| Debt/Equity Ratio | 0.7% |
How did VTGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 13:20 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vistagen Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Andrew Tsai | Jefferies LLC |
| Elemer Piros | Lucid Capital Markets |